Kimryn Rathmell
#167,832
Most Influential Person Now
Physician scientist
Kimryn Rathmell's AcademicInfluence.com Rankings
Kimryn Rathmellphilosophy Degrees
Philosophy
#10091
World Rank
#13800
Historical Rank
Logic
#7032
World Rank
#8646
Historical Rank
Kimryn Rathmellbiology Degrees
Biology
#13805
World Rank
#17386
Historical Rank
Molecular Biology
#2362
World Rank
#2398
Historical Rank
Download Badge
Philosophy Biology
Kimryn Rathmell's Degrees
- Doctorate Medicine University of North Carolina at Chapel Hill
- PhD Molecular Biology University of North Carolina at Chapel Hill
Why Is Kimryn Rathmell Influential?
(Suggest an Edit or Addition)According to Wikipedia, W. Kimryn Rathmell is an American physician-scientist whose work focuses on the research and treatment of patients with kidney cancers. She is the Hugh Jackson Morgan Professor and Chair of the Department of Medicine at Vanderbilt University Medical Center , and Physician-in-Chief for Vanderbilt University Adult Hospital and Clinics in Nashville, Tennessee. On Nov. 17, 2023, Rathmell was announced as the intended next Director of the National Cancer Institute.
Kimryn Rathmell's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Comprehensive molecular portraits of human breast tumors (2012) (7791)
- Comprehensive molecular characterization of gastric adenocarcinoma (2014) (4496)
- Comprehensive molecular profiling of lung adenocarcinoma (2014) (4095)
- Integrated genomic characterization of endometrial carcinoma (2013) (3708)
- Comprehensive genomic characterization of squamous cell lung cancers (2012) (2998)
- Comprehensive genomic characterization of head and neck squamous cell carcinomas (2015) (2860)
- Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. (2015) (2211)
- Genomic Classification of Cutaneous Melanoma (2015) (2143)
- The Molecular Taxonomy of Primary Prostate Cancer (2015) (2116)
- Integrated Genomic Characterization of Papillary Thyroid Carcinoma (2014) (2007)
- Comprehensive molecular characterization of urothelial bladder carcinoma (2014) (1748)
- Comprehensive molecular characterization of clear cell renal cell carcinoma (2013) (1724)
- Oncogenic Signaling Pathways in The Cancer Genome Atlas (2018) (1646)
- Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma (2017) (1514)
- Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma (2016) (1474)
- Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer (2017) (1446)
- Comprehensive Characterization of Cancer Driver Genes and Mutations (2018) (1360)
- Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer (2015) (1332)
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis (2018) (1232)
- Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. (2017) (1092)
- Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. (2016) (931)
- Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas (2016) (826)
- Integrated genomic and molecular characterization of cervical cancer (2017) (762)
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma (2018) (750)
- The somatic genomic landscape of chromophobe renal cell carcinoma. (2014) (646)
- Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas (2017) (577)
- Pathogenic Germline Variants in 10,389 Adult Cancers (2018) (501)
- The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma (2018) (480)
- Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients (2018) (471)
- Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. (2017) (460)
- HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. (2008) (455)
- Renal cell carcinoma (2007) (419)
- Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. (2013) (390)
- Broad targeting of angiogenesis for cancer prevention and therapy (2015) (387)
- Patterns of somatic structural variation in human cancer genomes (2020) (377)
- Restoration of X-ray resistance and V(D)J recombination in mutant cells by Ku cDNA. (1994) (353)
- Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism (2018) (350)
- Renal cell carcinoma (2014) (310)
- In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. (2013) (274)
- Cell-programmed nutrient partitioning in the tumour microenvironment (2020) (268)
- Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma (2010) (250)
- ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma. (2014) (219)
- Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead (2015) (219)
- Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma. (2017) (214)
- Involvement of the Ku autoantigen in the cellular response to DNA double-strand breaks. (1994) (201)
- Comprehensive molecular characterization of mitochondrial genomes in human cancers (2017) (197)
- Designing a broad-spectrum integrative approach for cancer prevention and treatment. (2015) (194)
- Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. (2010) (188)
- Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context (2018) (188)
- Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns (2010) (181)
- AMPK Is Essential to Balance Glycolysis and Mitochondrial Metabolism to Control T-ALL Cell Stress and Survival. (2016) (181)
- A DNA end-binding factor involved in double-strand break repair and V(D)J recombination (1994) (177)
- Dual Chromatin and Cytoskeletal Remodeling by SETD2 (2016) (176)
- Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. (2007) (175)
- Clear cell renal cell carcinoma ontogeny and mechanisms of lethality (2020) (175)
- Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects (2014) (171)
- Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma (2018) (166)
- Ku86 defines the genetic defect and restores X-ray resistance and V(D)J recombination to complementation group 5 hamster cell mutants (1996) (165)
- Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. (2003) (160)
- State of the Science: An Update on Renal Cell Carcinoma (2012) (146)
- Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. (2010) (145)
- Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. (2021) (139)
- VHL gene mutations in renal cell carcinoma: Role as a biomarker of disease outcome and drug efficacy (2009) (135)
- von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythropoiesis. (2007) (122)
- Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma (2009) (117)
- The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy (2020) (115)
- Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. (2018) (113)
- Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology. (2012) (102)
- VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma (2018) (102)
- Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. (2008) (98)
- DNA-dependent protein kinase is not required for accumulation of p53 or cell cycle arrest after DNA damage. (1997) (90)
- Erratum: Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles (Cell Reports (2017) 18(11) (2780–2794) (S2211124717302140) (10.1016/j.celrep.2017.02.033)) (2017) (88)
- PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma (2020) (88)
- The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. (2018) (86)
- Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages (2021) (77)
- Ror2 as a therapeutic target in cancer. (2015) (74)
- A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. (2013) (74)
- VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment (2008) (72)
- Racial difference in histologic subtype of renal cell carcinoma (2013) (71)
- In vitro and In vivo Models Analyzing von Hippel-Lindau Disease-Specific Mutations (2004) (69)
- Regulation of KLF4 turnover reveals an unexpected tissue-specific role of pVHL in tumorigenesis. (2012) (67)
- Modeling Clear Cell Renal Cell Carcinoma and Therapeutic Implications (2020) (66)
- Basic research in kidney cancer. (2011) (63)
- Renal cell carcinoma (2005) (60)
- Epigenetic modifiers: activities in renal cell carcinoma (2018) (60)
- Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancers (2019) (59)
- The molecular biology of renal cell carcinoma. (2013) (58)
- Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups (2016) (57)
- Structure/Function Analysis of Recurrent Mutations in SETD2 Protein Reveals a Critical and Conserved Role for a SET Domain Residue in Maintaining Protein Stability and Histone H3 Lys-36 Trimethylation* (2016) (55)
- From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. (2021) (55)
- Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. (2019) (54)
- Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study (2017) (53)
- Associations between Tumor Vascularity, Vascular Endothelial Growth Factor Expression and PET/MRI Radiomic Signatures in Primary Clear-Cell–Renal-Cell-Carcinoma: Proof-of-Concept Study (2017) (52)
- Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. (2017) (52)
- Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling (2017) (48)
- FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer (2013) (48)
- Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead (2015) (45)
- High-dose-intensity MVAC for Advanced Renal Medullary Carcinoma: Report of Three Cases and Literature Review. (2008) (44)
- Renal Medullary Carcinoma: Establishing Standards in Practice. (2017) (44)
- COVID-19 impact on early career investigators: a call for action (2020) (43)
- Renal cell carcinoma (2006) (43)
- Sex differences in oncogenic mutational processes (2019) (41)
- SETD2 Haploinsufficiency for Microtubule Methylation Is an Early Driver of Genomic Instability in Renal Cell Carcinoma. (2018) (41)
- Biological Aspects and Binding Strategies of Vascular Endothelial Growth Factor in Renal Cell Carcinoma (2007) (41)
- Recent updates in renal cell carcinoma (2010) (41)
- Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesis. (2015) (40)
- VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo (2009) (40)
- Failure of Hairpin-Ended and Nicked DNA To Activate DNA-Dependent Protein Kinase: Implications for V(D)J Recombination (1998) (40)
- Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma (2017) (39)
- Molecularly targeted therapy in renal cell carcinoma (2005) (38)
- Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. (2019) (37)
- Strategies to overcome therapeutic resistance in renal cell carcinoma. (2017) (37)
- Phase II trial of sorafenib plus interferon-alpha 2b (IFN-α2b) as first- or second-line therapy in patients (pts) with metastatic renal cell cancer (RCC). (2006) (37)
- CD28 costimulation drives tumor-infiltrating T cell glycolysis to promote inflammation (2020) (36)
- Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline (2022) (36)
- Diagnostic accuracy of contrast-enhanced ultrasound for characterization of kidney lesions in patients with and without chronic kidney disease (2017) (35)
- Ultrasound Molecular Imaging of VEGFR-2 in Clear-Cell Renal Cell Carcinoma Tracks Disease Response to Antiangiogenic and Notch-Inhibition Therapy (2018) (32)
- Metabolic Alterations in Cancer and Their Potential as Therapeutic Targets. (2017) (31)
- VHL Type 2B Mutations Retain VBC Complex Form and Function (2008) (30)
- Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma. (2018) (30)
- The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response. (2010) (29)
- Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau disease–associated renal cell carcinoma. (2020) (29)
- HIF transcription factor expression and induction of hypoxic response genes in a retroperitoneal angiosarcoma. (2004) (27)
- Management of Indeterminate Cystic Kidney Lesions: Review of Contrast-enhanced Ultrasound as a Diagnostic Tool. (2016) (27)
- Early heart development in the chick embryo: effects of isotretinoin on cell proliferation, alpha-actin synthesis, and development of contractions. (1992) (26)
- Ethical challenges: managing oncology drug shortages. (2013) (26)
- Identification of Ror2 as a Hypoxia-inducible Factor Target in von Hippel-Lindau-associated Renal Cell Carcinoma* (2010) (26)
- ClearCode 34 : A Prognostic Risk Predictor for Localized Clear Cell Renal Cell Carcinoma (2014) (25)
- Metabolic Pathways in Kidney Cancer: Current Therapies and Future Directions. (2018) (25)
- Renal cancer subtypes: Should we be lumping or splitting for therapeutic decision making? (2017) (25)
- Primary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib (2012) (25)
- Positron emission tomography in renal cell carcinoma: an imaging biomarker in development. (2012) (25)
- Integrative radiomics expression predicts molecular subtypes of primary clear cell renal cell carcinoma. (2018) (25)
- DNA hypomethylation promotes transposable element expression and activation of immune signaling in renal cell cancer. (2020) (25)
- Insights into the Genetic Basis of the Renal Cell Carcinomas from The Cancer Genome Atlas (2016) (24)
- Fine-Needle Aspiration-Based Patient-Derived Cancer Organoids (2020) (24)
- Receptor Tyrosine Kinase-like Orphan Receptor 2 (Ror2) Expression Creates a Poised State of Wnt Signaling in Renal Cancer* (2013) (23)
- Beyond glycolysis: Hypoxia signaling as a master regulator of alternative metabolic pathways and the implications in clear cell renal cell carcinoma. (2020) (23)
- A Pilot Clinical Study in Characterization of Malignant Renal-cell Carcinoma Subtype with Contrast-enhanced Ultrasound (2017) (23)
- Genomics of chromophobe renal cell carcinoma: implications from a rare tumor for pan-cancer studies (2015) (23)
- Context-dependent role for chromatin remodeling component PBRM1/BAF180 in clear cell renal cell carcinoma (2017) (23)
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (22)
- Physician and stakeholder perceptions of conflict of interest policies in oncology. (2013) (22)
- Patients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbidities. (2016) (22)
- Set2 methyltransferase facilitates cell cycle progression by maintaining transcriptional fidelity (2017) (21)
- Von Hippel-Lindau mutations disrupt vascular patterning and maturation via Notch. (2018) (21)
- Tumor suppressive activity of prolyl isomerase Pin1 in renal cell carcinoma (2011) (21)
- Systematic Review: ClearCode 34 – A Validated Prognostic Signature in Clear Cell Renal Cell Carcinoma (ccRCC) (2018) (21)
- Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial. (2011) (21)
- Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry–Based Phosphotyrosine Proteomics (2016) (21)
- Pleiotropic Effects of the Trichloroethylene-Associated P81S VHL Mutation on Metabolism, Apoptosis, and ATM-Mediated DNA Damage Response (2013) (21)
- Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma (2018) (20)
- Epstein-Barr Virus Latent Membrane Protein 1 is not Associated with Vessel Density nor with Hypoxia Inducible Factor 1 Alpha Expression in Nasopharyngeal Carcinoma Tissue (2009) (20)
- Renal Cell Carcinoma: Where Will the State-of-the-Art Lead Us? (2010) (20)
- Macrophages Promote Aortic Valve Cell Calcification and Alter STAT3 Splicing (2020) (20)
- Expression of Ror2 Mediates Invasive Phenotypes in Renal Cell Carcinoma (2014) (19)
- Looking beyond inhibition of VEGF/mTOR: emerging targets for renal cell carcinoma drug development. (2011) (19)
- The therapeutic implications of immunosuppressive tumor aerobic glycolysis (2021) (19)
- Alternate Metabolic Programs Define Regional Variation of Relevant Biological Features in Renal Cell Carcinoma Progression (2016) (19)
- Correlation of degree of tumor immune infiltration and insertion-and-deletion (indel) burden with outcome on programmed death 1 (PD1) therapy in advanced renal cell cancer (RCC). (2018) (18)
- HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas. (2017) (18)
- Phase I study of concurrent weekly docetaxel, high‐dose intensity‐modulated radiation therapy (IMRT) and androgen‐deprivation therapy (ADT) for high‐risk prostate cancer (2012) (18)
- The Huntingtin-interacting protein SETD2/HYPB is an actin lysine methyltransferase (2020) (18)
- Evaluation, diagnosis and surveillance of renal masses in the setting of VHL disease (2020) (17)
- Using molecular biology to develop drugs for renal cell carcinoma (2008) (16)
- Ultrasound Measurement of Vascular Density to Evaluate Response to Anti-Angiogenic Therapy in Renal Cell Carcinoma (2019) (15)
- Kidney cancer. (2012) (15)
- Mechanisms for DNA Double-Strand Break Repair in Eukaryotes (1998) (15)
- Genomic investigation of etiologic heterogeneity: methodologic challenges (2014) (15)
- Ethical considerations for the clinical oncologist in an era of oncology drug shortages. (2014) (14)
- Impact of the influenza vaccination on cancer patients undergoing therapy with immune checkpoint inhibitors (ICI). (2018) (14)
- HIF1α and HIF2α Exert Distinct Nutrient Preferences in Renal Cells (2014) (14)
- Pilot Study of [18F] Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)/Magnetic Resonance Imaging (MRI) for Staging of Muscle-invasive Bladder Cancer (MIBC). (2020) (14)
- Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings. (2015) (14)
- A phase II trial of lapatinib in hormone refractory prostate cancer (2008) (13)
- Transformation to Academic Leadership: The Role of Mentorship and Executive Coaching. (2019) (13)
- Summary from the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research. (2020) (13)
- Methylated α-tubulin antibodies recognize a new microtubule modification on mitotic microtubules (2016) (13)
- A cytoskeletal function for PBRM1 reading methylated microtubules (2020) (12)
- Roadmap for the development of the University of North Carolina at Chapel Hill Genitourinary OncoLogy Database--UNC GOLD. (2014) (12)
- Phase II Trial of 5-Fluorouracil and Leucovorin in Combination With Interferon-alpha and Interleukin-2 for Advanced Renal Cell Cancer (2004) (12)
- Prospective phase II multi-center study of individualized axitinib (Axi) titration for metastatic renal cell carcinoma (mRCC) after treatment with PD-1 / PD-L1 inhibitors. (2018) (11)
- Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC). (2021) (11)
- Apoptolidin family glycomacrolides target leukemia through inhibition of ATP synthase (2021) (11)
- Outcome of patients (pts) with renal medullary carcinoma (RMC) treated in the era of targeted therapies (TT): A multicenter experience. (2011) (10)
- VHL and PTEN loss coordinate to promote mouse liver vascular lesions (2010) (10)
- Neuronal SETD2 activity links microtubule methylation to an anxiety-like phenotype in mice. (2021) (10)
- Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma (2021) (10)
- The 2019 Nobel Prize honors fundamental discoveries in hypoxia response. (2019) (10)
- PET/CT with (124)I-cG250: great potential and some open questions. (2014) (9)
- Neoadjuvant treatment of renal cell carcinoma. (2010) (9)
- Kidney cancer: Rest ASSUREd, much can be learned from adjuvant studies in renal cancer (2016) (8)
- Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma (2020) (8)
- A phase II biomarker assessment of tivozanib in oncology (BATON) trial in patients (pts) with advanced renal cell carcinoma (RCC). (2012) (8)
- Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma (2021) (7)
- Triticarte: whole-genome profiling service for wheat and barley using Diversity Arrays Technology (DArT) (2006) (6)
- SETD2 loss sensitizes cells to PI3Kβ and AKT inhibition (2019) (6)
- Macrophages Promote Aortic Valve Cell Calcification and Alter STAT3 (Signal Transducer and Activator of Transcription 3) Splicing. (2020) (6)
- Alterations in key clear cell renal cell carcinoma (RCC) genes to refine patient prognosis. (2018) (6)
- VHL: oxygen sensing and vasculogenesis (2005) (6)
- Metabolic Alterations in Cancer and Their Potential as Therapeutic Targets. (2017) (6)
- Molecular determinants for α-tubulin methylation by SETD2 (2020) (6)
- Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC). (2019) (6)
- LBA26 Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC): Update on RCC and non-RCC disease (2020) (5)
- Ligand-independent integrin β1 signaling supports lung adenocarcinoma development (2022) (5)
- A Predictor for Survival in Intermediate Grade Clear Cell Renal Cell Carcinoma (2009) (5)
- FDG-PET as a predictive marker for therapy with everolimus in metastatic renal cell cancer (mRCC). (2011) (4)
- Renal Cell Carcinoma (2012) (4)
- Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement (2021) (4)
- Emerging molecular classification in renal cell carcinoma: implications for drug development (2010) (4)
- Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure. (2020) (4)
- Balancing dual demands on the physician-scientist workforce. (2018) (4)
- Biomarkers for Renal Cell Carcinoma (2012) (4)
- Uropathogenic Escherichia coli subverts mitochondrial metabolism to enable intracellular bacterial pathogenesis in urinary tract infection (2022) (4)
- Elevated transferrin receptor impairs T cell metabolism and function in systemic lupus erythematosus (2023) (4)
- Uniting Molecular Biomarkers to Advance the Science and Care of Clear Cell Renal Cell Carcinoma (2014) (4)
- Integrative computational immunogenomic profiling of cortisol‐secreting adrenocortical carcinoma (2021) (3)
- State-ofthe-science : An update on renal cell carcinoma (2012) (3)
- Sunitinib and Axitinib increase secretion and glycolytic activity of small extracellular vesicles in renal cell carcinoma (2021) (3)
- Expression of endogenous retroviruses and response to immune checkpoint therapy in renal cell cancer. (2018) (3)
- Use of meta-analysis of clear cell renal cell carcinoma gene expression to define a variant subgroup and identify gender influences on tumor biology. (2012) (3)
- Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer (2022) (3)
- Molecular subtypes of clear cell renal cell carcinoma: Impact of diabetes mellitus, metformin, and immunotherapy on patient outcomes. (2014) (3)
- Patient-reported outcomes on treatment-related side effects in renal cell carcinoma. (2020) (2)
- Empowering ASCI's support of physician-scientists through stronger institutional connections. (2019) (2)
- Von Hippel-Lindau status influences phenotype of liver cancers arising from PTEN loss (2015) (2)
- Use of meta-analysis of clear cell renal cell carcinoma gene expression to define a variant subgroup and identify gender influences on tumor biology. (2012) (2)
- 1723PThe role of hepatocyte nuclear factor 1 homeobox B (HNF1B) loss in chromophobe RCC (ChRCC) development (2017) (2)
- A global view of the aspiring physician-scientist (2022) (2)
- A Case Report of Severe Type B Lactic Acidosis Following First Dose of Nivolumab in a VHL-Mutated Metastatic Renal Cell Carcinoma (2017) (2)
- Phase II study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC). (2021) (2)
- SETD2 regulates the methylation of translation elongation factor eEF1A1 in clear cell renal cell carcinoma (2020) (2)
- Pearls of wisdom for aspiring physician-scientist residency applicants and program directors (2022) (2)
- A tale of two cancers: Complete genetic analysis of chromophobe renal cell carcinoma contrasts with clear cell renal cell carcinoma (2015) (2)
- Seeing the Forest for the Trees: Kidney Oncogenomes in Relation to Therapeutic Outcomes (2014) (2)
- Genomic Assessment of Renal Cancer (2015) (1)
- The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma (2022) (1)
- Proteomic stratification of clear cell renal cell carcinoma utilizing The Cancer Genome Atlas (TCGA) with external validation. (2015) (1)
- Phase II study of alternate sunitinib schedule in patients with metastatic renal cell carinoma. (2017) (1)
- A validated 34-gene signature for assessing risk of recurrence in clear cell renal cell carcinoma. (2013) (1)
- Management and outcomes of patients with renal medullary carcinoma (RMC): A multicenter retrospective study of 39 patients. (2015) (1)
- Metabolic barriers to immunotherapy in renal cell carcinoma. (2017) (1)
- The role of mTOR and hypoxia pathway activation in promoting tumorigenesis of intrahepatic cholangiocarcinoma. (2011) (1)
- 233PPHASE 2 CLINICAL EVALUATION OF PRECLINICALLY DEFINED BIOMARKERS FOR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) TYROSINE KINASE INHIBITOR (TKI) TIVOZANIB IN RENAL CELL CARCINOMA (RCC). (2014) (1)
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma (2018) (1)
- Renal cell carcinoma. (2007) (1)
- A phase II study of alternative sunitinib scheduling in patients with metastatic renal cell carcinoma. (2017) (1)
- Response to neoadjuvant therapy with sorafenib in renal cell carcinoma (RCC) correlates with FDG uptake on pre-therapy PET CT (2010) (1)
- Multiplatform Computational Analysis of Mast Cells in Adrenocortical Carcinoma Tumor Microenvironment (2021) (1)
- Carcinoma in a cadaveric transplant kidney. (2012) (1)
- Multiplatform computational analysis of mast cells in adrenocortical carcinoma tumor microenvironment. (2021) (1)
- SETD2 is an actin lysine methyltransferase (2020) (1)
- Association of baseline neutrophil-to-eosinophil ratio (NER) and neutrophil-to-lymphocyte ratio (NLR) with response to combination immunotherapy (IO) with ipilimumab plus nivolumab (ipi/nivo) in patients with metastatic renal cell carcinoma (mRCC). (2021) (1)
- Genomic alterations to refine prognostication of patients with metastatic renal cell carcinoma. (2018) (1)
- HIF Biology in RCC: Implications for Signaling, Disease Progression, and Treatment (2012) (1)
- A phase I/II study of vaccination with autologous dendritic cells (DCs) transfected with autologous amplified tumor-derived mRNA in patients with stage IV renal cell carcinoma (RCC) (2005) (1)
- Spatial models of tumour evolution (2021) (1)
- Abstract 4371: Integrated molecular characterization of pheochromocytoma and paraganglioma including a novel, recurrent and prognostic fusion gene (2016) (1)
- Nutrient partitioning in the tumor microenvironment and FDG-PET imaging (2020) (1)
- Targeting metabolic dysregulation of T cells in kidney cancer. (2020) (1)
- Author Correction: Pan-cancer analysis of whole genomes (2023) (1)
- Models of Von Hippel-Lindau tumor suppressor disease specific activity. (2004) (1)
- Untangling ccRCC prognosis with SLINKY (2017) (1)
- Models of Von Hippel-Lindau tumor suppressor disease specific activity (2004) (1)
- Glutathione peroxidase 4 inhibition induces ferroptosis and mTOR pathway suppression in thyroid cancer (2022) (1)
- The Medical Scientist Training Program (MSTP): A Brief History and UNC's Recent MSTP Renewal (2014) (0)
- Macrophages Promote Aortic Valve Cell Calcification Through STAT3 Splicing (2020) (0)
- ACSS2 Regulates HIF-2α Degradation through the E3-Ubiquitin Ligase MUL1 in Clear Cell Renal Cell Carcinoma (2022) (0)
- MP23-09 INTEGRATED ANALYSIS OF METASTATIC DISEASE IN CLEAR CELL RENAL CELL CARCINOMA: A COLLABORATIVE TCGA ANALYSIS (2014) (0)
- Cancer Poised State of Wnt Signaling in Renal Receptor 2 ( Ror 2 ) Expression Creates a Receptor Tyrosine Kinase-like Orphan Molecular Bases of Disease : (2013) (0)
- 360 POSTER Ror2 in renal cell carcinoma: evaluating its role in RCC tumorigenesis (2008) (0)
- Association of the neutrophil to eosinophil ratio with response to immunotherapy-based combinations in metastatic renal cell carcinoma. (2021) (0)
- Abstract 1958: Early treatment response detected in a murine clear cell renal cell carcinoma model in response to combination therapy with antiangiogenic and notch inhibition therapy using a non-invasive imaging tool (2019) (0)
- Integrated genomic characterization of oesophageal carcinoma (2017) (0)
- A quantitative approach to characterizing malignant renal cell carcinoma using contrast enhanced ultrasound (2017) (0)
- Abstract 5989: Metabolic heterogeneity of the tumor microenvironment (2020) (0)
- patientswhomightpreferentiallybenefitfromPD-1/PD-L1blockadeorimmunotherapiesmorebroadly. Legalentityresponsibleforthestudy: KanazawaUniversity 1722P Loss of SWI/SNF chromatin remodelling complex is linked to advanced urinary bladder cancer (2017) (0)
- 445 META-ANALYSIS OF CLEAR CELL RENAL CELL CARCINOMA GENE EXPRESSION DELINEATES SUBGROUPS (2012) (0)
- Mutation and tissue lineage lead to organ-specific cancer (2022) (0)
- Biology of Renal Cell Carcinoma (Vascular Endothelial Growth Factor, Mammalian Target of Rapamycin, Immune Aspects) (2013) (0)
- Association between on-treatment eosinophil dynamics and outcomes in metastatic renal cell carcinoma patients treated with ipilimumab/nivolumab. (2022) (0)
- Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (0)
- Author Correction: Inferring structural variant cancer cell fraction (2022) (0)
- Predicting Cancer Survival Using Expression Patterns (2010) (0)
- Abstract 1025: Aberrant TCR activation and altered metabolism drive decreased T cell cytokine production in IDH mutated acute myeloid leukemia (2020) (0)
- Urological Survey Urological Oncology : Adrenal , Renal , Ureteral and Retroperitoneal Tumors Re : ClearCode 34 : A Prognostic Risk Predictor for Localized Clear Cell Renal Cell Carcinoma (2014) (0)
- 443 CLEAR CELL RENAL CELL CARCINOMA DISPLAYS DIFFERENTIAL GENE EXPRESSION BASED ON GENDER (2012) (0)
- Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma (2021) (0)
- Abstract B48: Targeting SETD2 knockout cells: A synthetic lethal approach to treating ccRCC (2013) (0)
- DISTINCT MOLECULAR SUBTYPES OF CLEAR CELL RENAL CELL CARCINOMA IDENTIFIED BY SIMPLIFIED MRNA PROFILING PREDICTS CLINICAL OUTCOME (2009) (0)
- 906 Immunogenomic evaluation of clear cell renal carcinoma uncovers HK3 as a myeloid specific metabolic enzyme (2021) (0)
- Correction: SETD2 loss sensitizes cells to PI3Kβ and AKT inhibition (2019) (0)
- Multiplatform Integrative Analyses of Immunosuppressive Signatures in Cortisol-secreting Adrenocortical Carcinoma (2021) (0)
- Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma Graphical (0)
- Chromophobe Renal Cell Carcinoma (2018) (0)
- Phase I Study of Concurrent Weekly Docetaxel, Androgen Deprivation, and High-dose External Beam Radiation Therapy (RT) for High-risk Prostate Cancer (2010) (0)
- Analyzing the role of the novel kinase Ror2 in renal cell carcinoma (2007) (0)
- High Frequency of Ovarian Cyst Development in Vhl2B/+;Snf5+/- Mice. (2018) (0)
- MP14-17 UNDERREPORTING OF SIDE EFFECTS IN SYSTEMIC THERAPY FOR RENAL CELL CARCINOMA (2020) (0)
- VEGF: Biologic Aspects and Clinical Approaches (2009) (0)
- Abstract 3071: Exploring the molecular mechanism underlying SETD2-PI3Kβ synthetic-lethal interaction in renal cell carcinoma (RCC) (2017) (0)
- Review State of the Science : An Update on Renal Cell Carcinoma (2012) (0)
- Cell Reports Resource The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma (2018) (0)
- MP71-02 UTILITY OF CLEAR CELL RENAL CELL CARCINOMA GENE EXPRESSION SUBTYPES IN RISK-STRATIFYING T1 RENAL MASSES (2016) (0)
- Author Correction: The evolutionary history of 2,658 cancers (2023) (0)
- The Biology of Renal Cell Cancer (2011) (0)
- 86 – Cancer du testicule (2011) (0)
- Von Hippel-Lindau status influences phenotype of liver cancers arising from PTen loss adam B sendor (2015) (0)
- Erratum to: SETD2 Regulates the Methylation of Translation Elongation Factor eEF1A1 in Clear Cell Renal Cell Carcinoma (2023) (0)
- Erratum to Regulation of KLF4 Turnover Reveals an Unexpected Tissue-Specific Role of pVHL in Tumorigenesis [Molecular Cell, 45, (2012), 233-243] (2015) (0)
- The effect of gender and age on gene expression in sporadic renal cell carcinoma. (2011) (0)
- State of the Art : Novel Kidney Cancer Genes : PBRM 1 / Histone Modifiers (2015) (0)
- Abstract 1942: Synthetic lethal interaction between SETD2 loss and inhibition of PI3Kβ in clear cell renal cell carcinoma (ccRCC) (2018) (0)
- Recurrence and survival following preoperative sorafenib for advanced renal cell carcinoma. (2011) (0)
- Abstract 4495: DNA demethylation promotes ERV expression and activation of immune signaling in renal cell cancer cells (2020) (0)
- Neoadjuvant clinical trials for biomarker discovery: An old idea to solve a new problem (2007) (0)
- A role for fibronectin in the development of beat in chick embryo cardiogenesis (1991) (0)
- Abstract A07: Targeting SETD2 knockout cells: A synthetic lethal approach to treating ccRCC (2013) (0)
- The effect of loss of SETD2 on mitochondrial dysfunction in clear cell renal cell carcinoma. (2019) (0)
- Management and outcomes of patients with renal medullary carcinoma (RMC): A collaborative multi-center study of 52 patients. (2016) (0)
- Single-Cell VIPER Identifies Recurrence-Associated Renal Tumor Macrophages (2021) (0)
- Special Edition EAU-ICUD - Review - Kidney Cancer Basic Research in Kidney Cancer (2011) (0)
- Surgical ischemia and detection of clear cell renal cell carcinoma biomarkers. (2014) (0)
- Abstract 4276: Characterization of an ex vivo primary multicellular renal cell culture as a potential model system for renal cell carcinoma tumorigenesis (2011) (0)
- Evaluation of the effects of neoadjuvant pazopanib for renal cell carcinoma on intratumor genetic heterogeneity. (2015) (0)
- Abstract B059: SETD2-PI3Kβ synthetic lethality (2018) (0)
- Abstract B1: Hypoxia inducible factor (HIF) promotes reductive carboxylation by regulating citrate levels and renders VHL-deficient and hypoxic cells sensitive to glutamine deprivation (2013) (0)
- Defining molecular determinants of sensitivity to EGFR inhibition in urothelial carinoma. (2011) (0)
- Fear of cancer recurrence among patients and survivors diagnosed with localized renal cell carcinoma. (2020) (0)
- Members of the General Assembly , Economic Impact of University Cancer Research Fund The UCRF fuels (0)
- Spatial models of tumour evolution (2021) (0)
- Disruptions in the realm of medical science. (2020) (0)
- Life of the Marlows (2004) (0)
- Prognostic value of genomic signatures in metastatic Clear Cell Renal Cell Carcinoma (mRCC) using The Cancer Genome Atlas (TCGA) data. (2015) (0)
- Circulating mir-21 and mir-378 are predictive of progression-free survival (PFS) in patients treated with everolimus in metastatic renal cell cancer (mRCC). (2012) (0)
- Life of the Marlows: A True Story of Frontier Life of Early Days (2004) (0)
- RecombinationImplications for V(D)J To Activate DNA-Dependent Protein Failure of Hairpin-Ended and Nicked DNA (2013) (0)
- MP35-01 PROTEOMIC STRATIFICATION OF CLEAR CELL RENAL CELL CARCINOMA UTILIZING THE CANCER GENOME ATLAS (TCGA) WITH EXTERNAL VALIDATION (2015) (0)
- SETD2 safeguards the genome against isochromosome formation (2022) (0)
- Effectiveness of chemotherapy administration and time to cystectomy following neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) in the academic and community settings. (2015) (0)
- Upcycling the TCA cycle—rewiring tumour-associated fibroblasts (2021) (0)
- PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma (2020) (0)
- Subset-specific mitochondrial and DNA damage shapes T cell responses to fever and inflammation (2022) (0)
- Nutrient partitioning in the tumor microenvironment (2021) (0)
- The therapeutic implications of immunosuppressive tumor aerobic glycolysis (2021) (0)
- Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer (2022) (0)
- Engineering functional 3-dimensional patient-derived endocrine organoids for broad multiplatform applications. (2022) (0)
- STING-activating nanoparticles normalize the vascular-immune interface to potentiate cancer immunotherapy (2023) (0)
- Abstract B206: Ror2 as a therapeutic target in renal cell carcinoma and other invasive cancers. (2013) (0)
- Immunogenicity in renal cell carcinoma: shifting focus to alternative sources of tumour-specific antigens. (2023) (0)
- Fine Needle Aspiration Based Immune Organoids Recapitulate TME in clear cell Renal Cell Carcinoma (ccRCC) (2020) (0)
- Pushing the boundaries with collision collaboration: the marriage of ideas. (2021) (0)
- Abstract 1229: Deciphering molecular mechanisms of metastasis in renal cell carcinoma (2023) (0)
- Integrated analysis of metastatic disease in clear cell renal cell carcinoma: A collaborative TCGA analysis. (2014) (0)
- Abstract 2042: A cytoskeletal function for PBRM1: reading methylated microtubules to maintain genomic stability (2021) (0)
- Author Correction: Patterns of somatic structural variation in human cancer genomes (2020) (0)
- A Family of Glycosylated Macrolides Selectively Target Energetic Vulnerabilities in Leukemia (2021) (0)
- Chromatin looping and globin (2014) (0)
- Optimal treatment by invoking biologic clusters in renal cell carcinoma (OPTIC RCC). (2023) (0)
- PD-1 is induced on tumor-associated macrophages in obesity to directly restrain anti-tumor immunity (2022) (0)
This paper list is powered by the following services:
Other Resources About Kimryn Rathmell
What Schools Are Affiliated With Kimryn Rathmell?
Kimryn Rathmell is affiliated with the following schools:
